nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—Lisinopril—dilated cardiomyopathy	0.0994	0.532	CbGbCtD
Amantadine—ABCB1—Spironolactone—dilated cardiomyopathy	0.0875	0.468	CbGbCtD
Amantadine—Cerebration impaired—Furosemide—dilated cardiomyopathy	0.00841	0.0291	CcSEcCtD
Amantadine—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00715	0.0248	CcSEcCtD
Amantadine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00673	0.0233	CcSEcCtD
Amantadine—Ataxia—Spironolactone—dilated cardiomyopathy	0.00621	0.0215	CcSEcCtD
Amantadine—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00571	0.0198	CcSEcCtD
Amantadine—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00475	0.0164	CcSEcCtD
Amantadine—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00443	0.0153	CcSEcCtD
Amantadine—Mental disability—Furosemide—dilated cardiomyopathy	0.00429	0.0149	CcSEcCtD
Amantadine—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00409	0.0142	CcSEcCtD
Amantadine—Alopecia—Spironolactone—dilated cardiomyopathy	0.00403	0.014	CcSEcCtD
Amantadine—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00395	0.0137	CcSEcCtD
Amantadine—Lethargy—Furosemide—dilated cardiomyopathy	0.00366	0.0127	CcSEcCtD
Amantadine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00356	0.0123	CcSEcCtD
Amantadine—Irritability—Furosemide—dilated cardiomyopathy	0.00343	0.0119	CcSEcCtD
Amantadine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00341	0.0118	CcSEcCtD
Amantadine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00332	0.0115	CcSEcCtD
Amantadine—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.0033	0.0114	CcSEcCtD
Amantadine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00328	0.0114	CcSEcCtD
Amantadine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00327	0.0113	CcSEcCtD
Amantadine—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00325	0.0113	CcSEcCtD
Amantadine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00324	0.0112	CcSEcCtD
Amantadine—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00307	0.0106	CcSEcCtD
Amantadine—Eczema—Lisinopril—dilated cardiomyopathy	0.003	0.0104	CcSEcCtD
Amantadine—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00292	0.0101	CcSEcCtD
Amantadine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00291	0.0101	CcSEcCtD
Amantadine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00288	0.00999	CcSEcCtD
Amantadine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00283	0.00981	CcSEcCtD
Amantadine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0028	0.0097	CcSEcCtD
Amantadine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00269	0.00933	CcSEcCtD
Amantadine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00267	0.00926	CcSEcCtD
Amantadine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00267	0.00926	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—PSEN1—dilated cardiomyopathy	0.00266	0.00507	CbGpPWpGaD
Amantadine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00258	0.00894	CcSEcCtD
Amantadine—Irritability—Lisinopril—dilated cardiomyopathy	0.00257	0.00891	CcSEcCtD
Amantadine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00256	0.00888	CcSEcCtD
Amantadine—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00256	0.00887	CcSEcCtD
Amantadine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00253	0.00877	CcSEcCtD
Amantadine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00246	0.00852	CcSEcCtD
Amantadine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00245	0.0085	CcSEcCtD
Amantadine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00243	0.00843	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.00241	0.00459	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00239	0.00457	CbGpPWpGaD
Amantadine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00239	0.00829	CcSEcCtD
Amantadine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00239	0.00828	CcSEcCtD
Amantadine—GRIN2C—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00234	0.00447	CbGpPWpGaD
Amantadine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00232	0.00804	CcSEcCtD
Amantadine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00229	0.00795	CcSEcCtD
Amantadine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00227	0.00786	CcSEcCtD
Amantadine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00225	0.00781	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00223	0.00425	CbGpPWpGaD
Amantadine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00222	0.00769	CcSEcCtD
Amantadine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00222	0.00769	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.0022	0.00419	CbGpPWpGaD
Amantadine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00218	0.00754	CcSEcCtD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00218	0.00415	CbGpPWpGaD
Amantadine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00216	0.00749	CcSEcCtD
Amantadine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00215	0.00743	CcSEcCtD
Amantadine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00213	0.00736	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.0021	0.004	CbGpPWpGaD
Amantadine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00206	0.00714	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00206	0.00392	CbGpPWpGaD
Amantadine—Rash—Spironolactone—dilated cardiomyopathy	0.00205	0.00708	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.00204	0.0039	CbGpPWpGaD
Amantadine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00204	0.00708	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00204	0.00389	CbGpPWpGaD
Amantadine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00204	0.00706	CcSEcCtD
Amantadine—Headache—Spironolactone—dilated cardiomyopathy	0.00203	0.00704	CcSEcCtD
Amantadine—Agitation—Furosemide—dilated cardiomyopathy	0.00199	0.00688	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00195	0.00371	CbGpPWpGaD
Amantadine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00194	0.00671	CcSEcCtD
Amantadine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00194	0.0067	CcSEcCtD
Amantadine—GRIN2C—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00193	0.00368	CbGpPWpGaD
Amantadine—Nausea—Spironolactone—dilated cardiomyopathy	0.00193	0.00667	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.0019	0.00362	CbGpPWpGaD
Amantadine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00185	0.00642	CcSEcCtD
Amantadine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00184	0.00637	CcSEcCtD
Amantadine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00184	0.00636	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00183	0.00633	CcSEcCtD
Amantadine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00183	0.00633	CcSEcCtD
Amantadine—GRIN1—EPH-Ephrin signaling—PSEN2—dilated cardiomyopathy	0.00183	0.00348	CbGpPWpGaD
Amantadine—Dry mouth—Furosemide—dilated cardiomyopathy	0.0018	0.00624	CcSEcCtD
Amantadine—GRIN2D—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00179	0.00342	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00179	0.00341	CbGpPWpGaD
Amantadine—GRIN1—EPHB-mediated forward signaling—RAC1—dilated cardiomyopathy	0.00178	0.0034	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—PSEN2—dilated cardiomyopathy	0.00178	0.00339	CbGpPWpGaD
Amantadine—Confusional state—Furosemide—dilated cardiomyopathy	0.00178	0.00616	CcSEcCtD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00178	0.00339	CbGpPWpGaD
Amantadine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00176	0.00611	CcSEcCtD
Amantadine—GRIN2C—Neuronal System—ABCC9—dilated cardiomyopathy	0.00175	0.00335	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—RAC1—dilated cardiomyopathy	0.00174	0.00331	CbGpPWpGaD
Amantadine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00173	0.00599	CcSEcCtD
Amantadine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00171	0.00594	CcSEcCtD
Amantadine—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00171	0.00326	CbGpPWpGaD
Amantadine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00171	0.00591	CcSEcCtD
Amantadine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00169	0.00586	CcSEcCtD
Amantadine—GRIN2C—Neuronal System—ACTN2—dilated cardiomyopathy	0.00168	0.00321	CbGpPWpGaD
Amantadine—Anorexia—Furosemide—dilated cardiomyopathy	0.00168	0.00583	CcSEcCtD
Amantadine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00168	0.00582	CcSEcCtD
Amantadine—GRIN2A—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00168	0.0032	CbGpPWpGaD
Amantadine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00166	0.00577	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00165	0.00315	CbGpPWpGaD
Amantadine—Hypotension—Furosemide—dilated cardiomyopathy	0.00165	0.00571	CcSEcCtD
Amantadine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00165	0.0057	CcSEcCtD
Amantadine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00163	0.00566	CcSEcCtD
Amantadine—GRIN2D—Neuronal System—ABCC9—dilated cardiomyopathy	0.00163	0.00311	CbGpPWpGaD
Amantadine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00162	0.00562	CcSEcCtD
Amantadine—GRIN2C—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00162	0.00308	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—SCN5A—dilated cardiomyopathy	0.00161	0.00307	CbGpPWpGaD
Amantadine—Tension—Lisinopril—dilated cardiomyopathy	0.00159	0.00551	CcSEcCtD
Amantadine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00158	0.00549	CcSEcCtD
Amantadine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00158	0.00546	CcSEcCtD
Amantadine—Somnolence—Furosemide—dilated cardiomyopathy	0.00157	0.00543	CcSEcCtD
Amantadine—GRIN2B—Axon guidance—SCN5A—dilated cardiomyopathy	0.00157	0.00299	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—ACTN2—dilated cardiomyopathy	0.00156	0.00298	CbGpPWpGaD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00156	0.00297	CbGpPWpGaD
Amantadine—DRD2—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00155	0.00295	CbGpPWpGaD
Amantadine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00153	0.00531	CcSEcCtD
Amantadine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00153	0.0053	CcSEcCtD
Amantadine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00152	0.00528	CcSEcCtD
Amantadine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00152	0.0029	CbGpPWpGaD
Amantadine—Fatigue—Furosemide—dilated cardiomyopathy	0.00152	0.00527	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00152	0.0029	CbGpPWpGaD
Amantadine—Tremor—Lisinopril—dilated cardiomyopathy	0.00152	0.00526	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00152	0.00289	CbGpPWpGaD
Amantadine—Constipation—Furosemide—dilated cardiomyopathy	0.00151	0.00523	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—FAS—dilated cardiomyopathy	0.0015	0.00286	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00148	0.00282	CbGpPWpGaD
Amantadine—GRIN2A—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00147	0.00281	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00146	0.00279	CbGpPWpGaD
Amantadine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00145	0.00504	CcSEcCtD
Amantadine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00145	0.00503	CcSEcCtD
Amantadine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00143	0.00497	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00143	0.00272	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00143	0.00272	CbGpPWpGaD
Amantadine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00142	0.0027	CbGpPWpGaD
Amantadine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0014	0.00483	CcSEcCtD
Amantadine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00138	0.00477	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00137	0.00475	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00136	0.00258	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00135	0.00258	CbGpPWpGaD
Amantadine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00135	0.00468	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—ABCC9—dilated cardiomyopathy	0.00134	0.00256	CbGpPWpGaD
Amantadine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00134	0.00462	CcSEcCtD
Amantadine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00132	0.00459	CcSEcCtD
Amantadine—Oedema—Lisinopril—dilated cardiomyopathy	0.00132	0.00459	CcSEcCtD
Amantadine—DRD2—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.0013	0.00248	CbGpPWpGaD
Amantadine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0013	0.0045	CcSEcCtD
Amantadine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00129	0.00448	CcSEcCtD
Amantadine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00129	0.00445	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—ACTN2—dilated cardiomyopathy	0.00128	0.00245	CbGpPWpGaD
Amantadine—GRIN1—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00128	0.00245	CbGpPWpGaD
Amantadine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00128	0.00443	CcSEcCtD
Amantadine—Asthenia—Furosemide—dilated cardiomyopathy	0.00127	0.00439	CcSEcCtD
Amantadine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00126	0.00437	CcSEcCtD
Amantadine—DRD2—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00125	0.00239	CbGpPWpGaD
Amantadine—GRIN2B—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00125	0.00239	CbGpPWpGaD
Amantadine—Pruritus—Furosemide—dilated cardiomyopathy	0.00125	0.00432	CcSEcCtD
Amantadine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00124	0.00429	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00123	0.00235	CbGpPWpGaD
Amantadine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00121	0.00418	CcSEcCtD
Amantadine—Insomnia—Lisinopril—dilated cardiomyopathy	0.0012	0.00415	CcSEcCtD
Amantadine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00119	0.00412	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00118	0.00225	CbGpPWpGaD
Amantadine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00118	0.00409	CcSEcCtD
Amantadine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00118	0.00408	CcSEcCtD
Amantadine—GRIN1—Neuronal System—ABCC9—dilated cardiomyopathy	0.00117	0.00223	CbGpPWpGaD
Amantadine—Dizziness—Furosemide—dilated cardiomyopathy	0.00117	0.00404	CcSEcCtD
Amantadine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00117	0.00404	CcSEcCtD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00115	0.0022	CbGpPWpGaD
Amantadine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00115	0.00399	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00115	0.00219	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00114	0.00396	CcSEcCtD
Amantadine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00114	0.00395	CcSEcCtD
Amantadine—GRIN2B—Neuronal System—ABCC9—dilated cardiomyopathy	0.00114	0.00217	CbGpPWpGaD
Amantadine—Constipation—Lisinopril—dilated cardiomyopathy	0.00113	0.00392	CcSEcCtD
Amantadine—Vomiting—Furosemide—dilated cardiomyopathy	0.00112	0.00389	CcSEcCtD
Amantadine—GRIN1—Neuronal System—ACTN2—dilated cardiomyopathy	0.00112	0.00214	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00112	0.00213	CbGpPWpGaD
Amantadine—Rash—Furosemide—dilated cardiomyopathy	0.00111	0.00385	CcSEcCtD
Amantadine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00111	0.00385	CcSEcCtD
Amantadine—Headache—Furosemide—dilated cardiomyopathy	0.00111	0.00383	CcSEcCtD
Amantadine—GRIN2B—Neuronal System—ACTN2—dilated cardiomyopathy	0.00109	0.00208	CbGpPWpGaD
Amantadine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00109	0.00378	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00108	0.00205	CbGpPWpGaD
Amantadine—DRD2—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00105	0.00201	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00105	0.002	CbGpPWpGaD
Amantadine—Nausea—Furosemide—dilated cardiomyopathy	0.00105	0.00363	CcSEcCtD
Amantadine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00105	0.00363	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.001	0.00192	CbGpPWpGaD
Amantadine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000976	0.00338	CcSEcCtD
Amantadine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00095	0.00329	CcSEcCtD
Amantadine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000937	0.00324	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000935	0.00178	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—RAC1—dilated cardiomyopathy	0.000918	0.00175	CbGpPWpGaD
Amantadine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000906	0.00314	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—RAC1—dilated cardiomyopathy	0.000895	0.00171	CbGpPWpGaD
Amantadine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000876	0.00303	CcSEcCtD
Amantadine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000842	0.00292	CcSEcCtD
Amantadine—Rash—Lisinopril—dilated cardiomyopathy	0.000835	0.00289	CcSEcCtD
Amantadine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000834	0.00289	CcSEcCtD
Amantadine—Headache—Lisinopril—dilated cardiomyopathy	0.00083	0.00287	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000811	0.00155	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000803	0.00153	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00079	0.00151	CbGpPWpGaD
Amantadine—Nausea—Lisinopril—dilated cardiomyopathy	0.000787	0.00272	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000765	0.00146	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00076	0.00145	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000722	0.00138	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000709	0.00135	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000704	0.00134	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000696	0.00133	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000691	0.00132	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000686	0.00131	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—PSEN2—dilated cardiomyopathy	0.000678	0.00129	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000665	0.00127	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—PSEN2—dilated cardiomyopathy	0.000661	0.00126	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000653	0.00124	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000644	0.00123	CbGpPWpGaD
Amantadine—GRIN2D—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000638	0.00122	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000636	0.00121	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000618	0.00118	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000608	0.00116	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000593	0.00113	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000582	0.00111	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—ABCC9—dilated cardiomyopathy	0.000566	0.00108	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—ACTN2—dilated cardiomyopathy	0.000543	0.00104	CbGpPWpGaD
Amantadine—DDC—Metabolism—ANKRD1—dilated cardiomyopathy	0.000532	0.00101	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000524	0.000999	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000507	0.000968	CbGpPWpGaD
Amantadine—DDC—Metabolism—TAZ—dilated cardiomyopathy	0.0005	0.000953	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.0005	0.000953	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000484	0.000923	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000483	0.000922	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000472	0.0009	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000464	0.000886	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000457	0.000871	CbGpPWpGaD
Amantadine—DDC—Metabolism—SDHA—dilated cardiomyopathy	0.000452	0.000862	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ANKRD1—dilated cardiomyopathy	0.000447	0.000853	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000445	0.000849	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000443	0.000844	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000433	0.000825	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000431	0.000823	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—ITGB1—dilated cardiomyopathy	0.000424	0.000809	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000422	0.000804	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TAZ—dilated cardiomyopathy	0.000421	0.000802	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—ITGB1—dilated cardiomyopathy	0.000414	0.000789	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000407	0.000776	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—RAF1—dilated cardiomyopathy	0.000383	0.00073	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000381	0.000727	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SDHA—dilated cardiomyopathy	0.00038	0.000725	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000361	0.000689	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000357	0.000681	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000357	0.000681	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—RAF1—dilated cardiomyopathy	0.000356	0.000679	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000351	0.00067	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000351	0.00067	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000348	0.000664	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—RAC1—dilated cardiomyopathy	0.000341	0.00065	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000341	0.00065	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000337	0.000642	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000333	0.000634	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—RAC1—dilated cardiomyopathy	0.000332	0.000634	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000332	0.000633	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000332	0.000632	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000331	0.000632	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000327	0.000625	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000327	0.000625	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000327	0.000623	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000324	0.000618	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000317	0.000604	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000308	0.000588	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000308	0.000588	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000306	0.000583	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000304	0.000581	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000303	0.000577	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000299	0.000569	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000295	0.000563	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—RAF1—dilated cardiomyopathy	0.000292	0.000557	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000284	0.000542	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000284	0.000542	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000265	0.000505	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000264	0.000504	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CD36—dilated cardiomyopathy	0.000258	0.000493	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000256	0.000488	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000255	0.000486	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—RAF1—dilated cardiomyopathy	0.000255	0.000486	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CD36—dilated cardiomyopathy	0.000252	0.00048	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—RAF1—dilated cardiomyopathy	0.000248	0.000474	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—RAC1—dilated cardiomyopathy	0.000243	0.000464	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000242	0.000461	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000237	0.000453	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—RAC1—dilated cardiomyopathy	0.000237	0.000452	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000234	0.000446	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—RAF1—dilated cardiomyopathy	0.000226	0.000431	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TAZ—dilated cardiomyopathy	0.000223	0.000426	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000221	0.000422	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—RAF1—dilated cardiomyopathy	0.00022	0.00042	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000218	0.000417	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000216	0.000413	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000216	0.000413	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TAZ—dilated cardiomyopathy	0.000208	0.000397	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000207	0.000395	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SDHA—dilated cardiomyopathy	0.000202	0.000385	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000201	0.000384	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000197	0.000376	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000195	0.000371	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000193	0.000369	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000192	0.000366	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000192	0.000366	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SDHA—dilated cardiomyopathy	0.000188	0.000359	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000178	0.00034	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000173	0.00033	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000166	0.000317	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—RAF1—dilated cardiomyopathy	0.000161	0.000308	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000161	0.000307	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000158	0.000301	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—RAF1—dilated cardiomyopathy	0.000157	0.0003	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000156	0.000298	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—dilated cardiomyopathy	0.000155	0.000296	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000154	0.000293	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—dilated cardiomyopathy	0.000151	0.000288	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000151	0.000288	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000148	0.000282	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—RAF1—dilated cardiomyopathy	0.000133	0.000253	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.00013	0.000247	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00013	0.000247	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—RAF1—dilated cardiomyopathy	0.000124	0.000236	CbGpPWpGaD
Amantadine—DDC—Metabolism—GPX1—dilated cardiomyopathy	0.000123	0.000234	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000122	0.000233	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000122	0.000233	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000122	0.000233	CbGpPWpGaD
Amantadine—DDC—Metabolism—CD36—dilated cardiomyopathy	0.00012	0.000228	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000117	0.000223	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000114	0.000217	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000111	0.000212	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000111	0.000212	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—dilated cardiomyopathy	0.000111	0.000211	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.00011	0.00021	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00011	0.00021	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—dilated cardiomyopathy	0.000108	0.000206	CbGpPWpGaD
Amantadine—DDC—Metabolism—AGT—dilated cardiomyopathy	0.000108	0.000205	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—dilated cardiomyopathy	0.000105	0.000201	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPX1—dilated cardiomyopathy	0.000103	0.000197	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000103	0.000197	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—dilated cardiomyopathy	0.000103	0.000196	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CD36—dilated cardiomyopathy	0.000101	0.000192	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.0001	0.000191	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	9.8e-05	0.000187	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.4e-05	0.000179	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AGT—dilated cardiomyopathy	9.06e-05	0.000173	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.92e-05	0.00017	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.54e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.1e-05	0.000154	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.39e-05	0.000141	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.12e-05	0.000136	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.92e-05	0.000132	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	6.72e-05	0.000128	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.64e-05	0.000127	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.61e-05	0.000126	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.56e-05	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.56e-05	0.000125	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.4e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.29e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.1e-05	0.000116	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	6.01e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.9e-05	0.000113	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPX1—dilated cardiomyopathy	5.48e-05	0.000105	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CD36—dilated cardiomyopathy	5.34e-05	0.000102	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPX1—dilated cardiomyopathy	5.11e-05	9.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.04e-05	9.62e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CD36—dilated cardiomyopathy	4.98e-05	9.49e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AGT—dilated cardiomyopathy	4.81e-05	9.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.78e-05	9.12e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AGT—dilated cardiomyopathy	4.48e-05	8.55e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.17e-05	7.95e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.11e-05	7.84e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.89e-05	7.42e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.71e-05	7.08e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	3.55e-05	6.77e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3e-05	5.71e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.92e-05	5.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.86e-05	5.45e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.63e-05	5.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.46e-05	4.7e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.69e-05	3.22e-05	CbGpPWpGaD
